Jovanovic, Dragana (58721901700)Dragana (58721901700)JovanovicMilenkovic, Marina Roksandic (56157719200)Marina Roksandic (56157719200)MilenkovicStevuljevic, Jelena Kotur (36629424300)Jelena Kotur (36629424300)StevuljevicMarkovic, Jelena (54793088700)Jelena (54793088700)MarkovicCeriman, Vesna (57204881031)Vesna (57204881031)CerimanKontic, Milica (43761339600)Milica (43761339600)KonticTrifunovic, Vesna Skodric (35273464900)Vesna Skodric (35273464900)Trifunovic2025-06-122025-06-122018https://doi.org/10.21037/jtd.2018.11.16https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059540040&doi=10.21037%2fjtd.2018.11.16&partnerID=40&md5=e388e68d9631afc2d6c9296b3e83e8f4https://remedy.med.bg.ac.rs/handle/123456789/5961Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker. © Journal of Thoracic Disease. All rights reserved.Idiopathic pulmonary fibrosis (IPF)Membrane PD-L1 expressionSoluble PD-L1